Stock Groups

Novartis sees annual sales growth of 4% until 2026 -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: This sign is located at the Novartis Institutes for BioMedical Research, Cambridge, Massachusetts. It was taken on June 16, 2021. REUTERS/Brian Snyder/File Photo

ZURICH (Reuters), – Novartis, a Swiss pharmaceutical company, stated in a Thursday presentation that it is optimistic about reaching a core margin of innovative drugs in the upper 30s by 2026. The company also expects to grow its sales each year by 4% until then.

Novartis stated that it now has 20 assets under its control, with approval due by 2026. This could generate sales of at least 1$Billion.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses as a result.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]